Sarcoma, NOSs most frequently harbor alterations in TP53, CDKN2A, CDKN2B, ATRX, and RB1 .
TP53 Mutation, CDKN2A Loss, TP53 Missense, CDKN2B Loss, and TP53 c.217-c.1178 Missense are the most common alterations in sarcoma, NOS .
There is 1 clinical trial for sarcoma, NOS, of which 0 are open and 1 is completed or closed. Of the trial that contains sarcoma, NOS as an inclusion criterion, 1 is phase 2 (0 open).
9-ing-41, docetaxel, and gemcitabine are the most common interventions in sarcoma, NOS clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.